Results 181 to 190 of about 224,912 (319)

Stem Cells From Dental Pulp, Periodontal Tissues, and Other Oral Sources: Biological Concepts and Regenerative Potential

open access: yesJournal of Periodontal Research, EarlyView.
A graphical abstract recapping the different sources of dental, periodontal, and other oral‐derived mesenchymal stromal cells (MSCs) and their regenerative mechanisms and potentials. The review's article findings bridge fundamental biological science with translational advances, highlighting the significance of MSCs in craniofacial regenerative ...
Karim M. Fawzy El‐Sayed   +6 more
wiley   +1 more source

The Role of Viruses in the Pathogenesis of Periodontitis

open access: yesJournal of Periodontal Research, EarlyView.
This narrative review aimed to summarize current evidence on the presence and potential pathogenic role of viruses in periodontitis. Design: Narrative Review; Population: Patients with periodontitis; Exposure: Detection of viruses in oral samples (biopsies, saliva, gingival crevicular fluid, subgingival plaque, blood); Outcome: Viral prevalence, load ...
Kim Natalie Stolte   +2 more
wiley   +1 more source

Shigella flexneri with Ciprofloxacin Resistance and Reduced Azithromycin Susceptibility, Canada, 2015

open access: yesEmerging Infectious Diseases, 2016
Christiane Gaudreau   +4 more
doaj   +1 more source

Prioritizing cefuroxime as empirical treatment in acute bacterial prostatitis: patient characteristics and outcome. [PDF]

open access: yesJAC Antimicrob Resist
Lecomte E   +6 more
europepmc   +1 more source

Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1

open access: bronze, 2012
Andreea M. Bujor   +7 more
openalex   +2 more sources

The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates

open access: yesJournal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The fluoroquinolone antimicrobial agents, enrofloxacin and marbofloxacin, were approved in the United States for cats in 1990 and 2001, respectively. In 2023, revised breakpoints for testing isolates from dogs were published. These canine breakpoints are discordant with the current feline breakpoints.
Mark G. Papich   +2 more
wiley   +1 more source

Augmentation of antibacterial activity of ciprofloxacin by bisabololoxide A encapsulated in polymeric nanoparticles against uropathogenic Escherichia coli. [PDF]

open access: yesBMC Biotechnol
Bazgosha M   +10 more
europepmc   +1 more source

Role of Ciprofloxacin as an Antitubercular Agent in Treatment of Pulmonary Tuberculosi [PDF]

open access: bronze, 2003
Jai Kishan   +2 more
openalex   +1 more source

Home - About - Disclaimer - Privacy